Peripheral Arterial Disease (PAD) and Peripheral Ischemia
Peripheral Arterial Disease (PAD)
Peripheral arterial disease (PAD) is a systemic vascular condition characterized by reduced blood flow to the lower extremities due to narrowing or obstruction of peripheral arteries. PAD most commonly results from atherosclerosis and reflects widespread arterial disease.
When arterial blood flow becomes restricted, tissues in the legs and feet may not receive sufficient oxygen and nutrients. This reduction in perfusion is referred to as peripheral ischemia.
Unlike isolated musculoskeletal pain, PAD is a manifestation of systemic vascular dysfunction and is associated with increased cardiovascular and cerebrovascular risk.
Epidemiology and Vascular Risk Factors
Peripheral arterial disease affects millions of individuals worldwide and becomes more prevalent with advancing age. Because PAD is closely linked to atherosclerosis, it frequently coexists with coronary artery disease and cerebrovascular disease.
Major risk factors include:
• Smoking
• Diabetes mellitus
• Hypertension
• Hyperlipidemia
• Chronic kidney disease
• Advanced age
• Family history of cardiovascular disease
Chronic exposure to these risk factors contributes to endothelial dysfunction, plaque formation, arterial stiffening, and impaired perfusion.
Individuals with PAD have an elevated risk of myocardial infarction and stroke due to the systemic nature of atherosclerotic disease.
Pathophysiology of Peripheral Ischemia
PAD develops when atherosclerotic plaque accumulates within peripheral arteries, leading to progressive luminal narrowing and reduced downstream perfusion pressure.
As arterial diameter decreases:
• Oxygen delivery to skeletal muscle declines
• Nutrient transport becomes impaired
• Metabolic waste clearance slows
• Microvascular compensation becomes limited
In early stages, symptoms occur during exertion when oxygen demand exceeds supply. In advanced stages, ischemia may persist even at rest, reflecting critically reduced perfusion.
Chronic hypoperfusion may contribute to inflammatory signaling, endothelial dysfunction, and impaired wound healing within affected tissues.
Common Signs and Symptoms
The clinical presentation of PAD varies depending on the severity of arterial obstruction and collateral circulation.
Common symptoms include:
• Intermittent claudication, or leg pain during walking
• Calf cramping relieved by rest
• Coldness in the lower extremities
• Reduced exercise tolerance
• Weak or absent peripheral pulses
• Changes in skin color, texture, or hair growth
• Non-healing wounds or ulcers in advanced cases
Symptom severity may not always correlate with anatomical severity, as collateral circulation can partially compensate in some individuals.
Disease Progression and Complications
PAD may progress from mild intermittent claudication to more advanced ischemic disease.
Advanced stages may include:
• Ischemic rest pain
• Non-healing ischemic ulcers
• Tissue loss
• Increased risk of infection
• Major amputation in severe cases
Severe PAD may progress to chronic limb-threatening ischemia (CLTI), a high-risk vascular condition requiring specialized multidisciplinary management.
PAD is also associated with elevated cardiovascular mortality due to underlying systemic atherosclerosis.
Diagnostic Evaluation
Diagnosis of PAD involves objective hemodynamic assessment and anatomical imaging.
Evaluation may include:
• Ankle-brachial index (ABI) testing
• Toe-brachial index in patients with noncompressible vessels
• Duplex ultrasound
• CT angiography
• MR angiography
• Conventional angiography
ABI testing is commonly used as an initial screening tool to quantify perfusion pressure differences between the upper and lower extremities.
Given the systemic nature of atherosclerosis, cardiovascular risk assessment is also recommended.
Standard of Care and Risk Management
Management of PAD focuses on improving functional status, reducing ischemic symptoms, and mitigating systemic cardiovascular risk.
Core components may include:
• Smoking cessation
• Supervised exercise therapy
• Antiplatelet therapy
• Lipid-lowering medications
• Blood pressure management
• Glycemic control in diabetic patients
In selected cases, revascularization may be indicated, including:
• Endovascular interventions such as angioplasty and stenting
• Surgical bypass procedures
Treatment decisions are individualized and guided by vascular specialists.
Investigational Clinical Research in Peripheral Arterial Disease
Hemostemix is a clinical-stage biotechnology company evaluating ACP-01, an investigational autologous cell product, in ischemic conditions including peripheral arterial disease.
ACP-01 is derived from a patient’s own blood and contains angiogenic precursor cells. In regulated clinical research settings, ACP-01 is being evaluated for its involvement in vascular signaling pathways associated with ischemic tissue environments.
Hemostemix’s basket protocol strategy is designed to evaluate ACP-01 across multiple ischemic conditions that share vascular insufficiency as a central mechanism.
ACP-01 remains investigational and has not been approved by the U.S. Food and Drug Administration.
Frequently Asked Questions
What causes peripheral arterial disease?
PAD is most commonly caused by atherosclerosis, a condition in which plaque builds up inside arteries and restricts blood flow.
Is PAD the same as coronary artery disease?
Both involve atherosclerosis. PAD affects arteries outside the heart, most commonly in the legs, while coronary artery disease affects the arteries supplying the heart.
Can PAD lead to amputation?
In advanced stages such as chronic limb-threatening ischemia, severe reduction in blood flow may increase the risk of tissue loss. Early vascular evaluation is important.
Is ACP-01 approved for PAD?
No. ACP-01 is investigational and has not been approved by the U.S. FDA. It is being evaluated in structured clinical research programs.
Disclaimer